In another recent investigation involving individuals with NSCLC who experienced ICI-pneumonitis, there was a rise in IgM antibody levels against ACHRG, the cholinergic receptor nicotinic gamma subunit, from the beginning of treatment to the onset of toxicity in these patients. This evidence concerns the gene CHRNG and pneumonitis.